Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 05 March 2012 | By Alexander Gaffney, RAC
The California Supreme Court is set to review a case on so-called 'pay for delay' settlements that see pharmaceutical manufacturers pay generic manufacturers to secure additional months of market exclusivity for their products.
The court will review a decade-old class-action lawsuit against Bayer over its pay for delay settlement to Barr Laboratories. Barr was reportedly planning to sell a generic version of Bayer's antibiotic, Cipro (ciprofloxacin).
The lawsuit alleges that the deal forced Californians to overpay for the drug in violation of California anti-trust law.
The suit follows years of attempts by the Federal Trade Commission (FTC) to ban the practice without success. The Obama administration has proposed to end the practice in its Fiscal Year 2013 budget, but the proposal is far from certain to pass in a Republican-controlled congress.
California Watch - State court to examine 'pay-for-delay' deals by drugmakers
Regulatory Focus - Administration Budget Forcefully Against 'Pay-For-Delay,' Industry
Tags: Anti-Competitive, Anti-Trust, Pay For Delay, Lawsuit, Pharmaceuticals, California, Latest News, Supreme Court